Be The First To
Northwest Biotherapeutics wants to bring out the killer in you. The development-stage firm's DCVax vaccine platform uses dendritic cells (a type of white blood cells) obtained from a patient's blood to program that patient's own T cells to kill cancer cells. Northwest Biotherapeutics' two DCVax product candidates are being targeted to treat brain and prostate cancer. Both candidates are in late-stage clinical trials. If successful, the therapies could work in conjunction with more traditional cancer treatments. Toucan Capital holds over 85% of the company's shares...
This is the employer's chance to tell you why you should work for them. The information provided is from their perspective.
Let us know if we're missing any workplace or industry recognition –